Cizzle Biotechnology shares slumped to a new 52-week low after the lung cancer test developer said its North American licensee is no longer expected to pay US$1.81 million by the end of 2026, with the amount pushed back to the end of 2027.
Shares in Cizzle Biotechnology Holdings (LSE:CIZ) fell sharply on 15 October 2026 after the company released an announcement titled "Update on Launch of Lung Cancer Test in USA" at 07:00. The announcement, flagged as containing inside information, said that its North American licensee, Cizzle Bio Inc ("BIO"), "is not expected to pay the full US$1.81 million to the Company by 31 December 2026 under that schedule." Under a "Variation" to the arrangement, that US$1.81 million is now due by 31 December 2027.
The company also warned that if minimum or advance royalty payments are delayed or not received, "the Company may need to seek alternative funding." The shares were trading at 0.975p, down 0.425p or 30.36% from the previous close of 1.40p, after hitting a new 52-week low of 0.95p. Volume reached 11,993,861 shares, and the market capitalisation stood at £4.14m. A later reading showed the shares at 1.025p, down 26.79%. Cizzle is one of the stocks drawing heavy discussion among UK investors today.
What changed in the licensing arrangement
Cizzle licenses its CIZ1B blood test to BIO for North America and earns a royalty of 10% of gross sales. Under the existing agreement, committed advance payments of US$2.4 million were due by 31 December 2026. The company received US$590,000 from BIO on 23 February 2026, made up of US$100,000 in exclusivity fees and US$490,000 in advance royalties. The remaining US$1.81 million has now been deferred to 31 December 2027.
The announcement set out several further terms:
- The US$490,000 already received, plus future advance royalties, will be treated as non-refundable upfront or milestone payments, so that Cizzle receives royalties from initial sales.
- The company may convert the deferred payments into BIO capital stock, either at the price of BIO's next fundraising or at fair market value.
- A further minimum of US$3.5 million in committed payments, linked to the extension to 2031 announced on 23 February 2026, is unaffected.
The company linked the delay to US policy changes. Measures announced on 25 February 2026, including the CRUSH Initiative RFI and a six-month moratorium on new Medicare enrolment for certain suppliers, "has resulted in disruption to operational capabilities at BIO's initial laboratory partner," according to the announcement.
Progress on the US launch
Despite the payment delay, the company pointed to commercial progress. The CIZ1B test has been validated in a CLIA-accredited laboratory. Its approval for clinical use at OmniHealth Diagnostics was announced on 16 June 2026, and it was made available to selected clinicians on 22 July 2026.
BIO has since signed a second CLIA laboratory, BioBridge Global in San Antonio, Texas, announced on 3 August 2026. BioBridge Global tests "over 50 million samples annually". Its subsidiary, BBG Advanced Therapies, will offer the test in South Texas once it completes its own independent validation, which has started. BIO is also in discussions with further CLIA laboratories.
Allan Syms, Executive Chairman, said in the latest announcement: "The Company has now moved from its R&D phase to commercialisation". He added: "The focus is now on securing early adoption in the USA private pay market".
The business at a glance
Cizzle is a UK diagnostics developer working on a blood-based test for the early detection of lung cancer, built on the CIZ1B biomarker. Its academic partner is the University of York, and the collaboration agreement has been renewed to 30 June 2027. The company earns royalties through licensing, with Cizzle Bio Inc covering North America and a separate Caribbean arrangement in place. It is also seeking partners in the UK, Europe and Asia-Pacific. The company was admitted to the Official List and Main Market of the London Stock Exchange in May 2021.
In its interim results, Cizzle said it had secured new US and Canadian patents, and that minimum royalties had increased to approximately US$5.9 million on renewal of the licensing agreement. A study at Moffitt Cancer Center is ongoing, with results presented in August 2026. Professor Dawn Coverley, Founder and Chief Scientific Officer, said that "seeing the CIZ1B test finally move from bench to clinic is wonderful."
A thin financial cushion
The payment delay matters because of the company's limited cash resources. For the six months to 30 June 2026, Cizzle reported:
- Revenue: nil
- Loss: £329k (H1 2025: £368k)
- Loss per share: 0.08p
- Net cash used in operations: £(367)k
- Cash: £81k (31 December 2025: £116k)
- Net assets: deficit of £337k
- Trade and other payables: £528k
The company received £350k from convertible loan notes during the first half. On 6 May 2026, £400k of convertible loan notes were converted into 28,571,429 new shares at 1.4p. Earlier, on 2 April 2026, Cizzle (LSE:CIZ) announced a funding facility of up to £250,000 in unsecured, interest-free convertible loan notes from existing investor Frazer Lang, convertible at 1.4p per share. The facility came with 10,000,000 warrants at 2.5p, exercisable within two years, taking his total warrant holding to 22,500,000.
Allan Syms described the first half as "a landmark period in the Company's history", but with revenue still at nil and cash at £81k at the half-year, the timing of payments from BIO is central to the funding outlook.
Risks to weigh
The latest announcement highlights several risks drawn from the company's own disclosures:
- Funding: cash was £81k and net assets were in deficit at 30 June 2026. The company has said it "may need to seek alternative funding" if BIO payments are delayed.
- Counterparty and timing: the deferral of US$1.81m to 31 December 2027 increases reliance on the licensee's future performance and payment.
- US regulatory and operational: federal measures have disrupted BIO's initial laboratory partner, showing how policy changes outside the company's control can affect the rollout.
- Dilution: convertible loan notes at 1.4p and warrants at 2.5p could increase the share count. Frazer Lang has said his stake would rise to about 21% on full conversion.
Any decision to take BIO stock in place of cash would also change the nature of what Cizzle receives, as the value of that stock would depend on BIO's own progress and fundraising.
What to watch next
Key areas of focus for shareholders include:
- Whether the company announces alternative funding arrangements
- Any decision on converting deferred payments into BIO capital stock
- Progress on BBG Advanced Therapies' independent validation in South Texas
- Further CLIA laboratory agreements signed by BIO
- Early sales and royalty income from US clinicians
The shares have fallen from a 52-week high of 3.75p, set on 13 May 2026, to today's low of 0.95p. Today's sharp move reflects the importance of near-term cash receipts for a company that has only recently moved into commercialisation, and future updates on BIO's payments and US adoption are likely to remain closely watched.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...